Similar efforts to characterize GBM have revealed that, whilst several molecular subtypes exist [4,8], only the glioma-CpG island methylated phenotype (G-CIMP), which harbor the IDH1-R132H mutation, is predictive of longer patient survival [9]. This evidence concerns the gene IDH1 and glioblastoma.